BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: El Alaoui-Lasmaili K, Faivre B. Antiangiogenic therapy: Markers of response, "normalization" and resistance. Crit Rev Oncol Hematol 2018;128:118-29. [PMID: 29958627 DOI: 10.1016/j.critrevonc.2018.06.001] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 6.0] [Reference Citation Analysis]
Number Citing Articles
1 deSouza NM, Achten E, Alberich-Bayarri A, Bamberg F, Boellaard R, Clément O, Fournier L, Gallagher F, Golay X, Heussel CP, Jackson EF, Manniesing R, Mayerhofer ME, Neri E, O'Connor J, Oguz KK, Persson A, Smits M, van Beek EJR, Zech CJ; European Society of Radiology. Validated imaging biomarkers as decision-making tools in clinical trials and routine practice: current status and recommendations from the EIBALL* subcommittee of the European Society of Radiology (ESR). Insights Imaging 2019;10:87. [PMID: 31468205 DOI: 10.1186/s13244-019-0764-0] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 4.7] [Reference Citation Analysis]
2 Rada M, Lazaris A, Kapelanski-Lamoureux A, Mayer TZ, Metrakos P. Tumor microenvironment conditions that favor vessel co-option in colorectal cancer liver metastases: A theoretical model. Semin Cancer Biol 2021;71:52-64. [PMID: 32920126 DOI: 10.1016/j.semcancer.2020.09.001] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
3 Lu BW, Xie LK. Potential applications of artemisinins in ocular diseases. Int J Ophthalmol 2019;12:1793-800. [PMID: 31741871 DOI: 10.18240/ijo.2019.11.20] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Zhang L, Chen Y, Li F, Bao L, Liu W. Atezolizumab and Bevacizumab Attenuate Cisplatin Resistant Ovarian Cancer Cells Progression Synergistically via Suppressing Epithelial-Mesenchymal Transition. Front Immunol 2019;10:867. [PMID: 31105696 DOI: 10.3389/fimmu.2019.00867] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 6.7] [Reference Citation Analysis]
5 Hajjo R, Sabbah DA, Bardaweel SK, Tropsha A. Identification of Tumor-Specific MRI Biomarkers Using Machine Learning (ML). Diagnostics (Basel) 2021;11:742. [PMID: 33919342 DOI: 10.3390/diagnostics11050742] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Lv G, Zhou Y, Zheng D, Gao J, Xu Z, Jiang L. Comparison of Model-Free and Model-Based Dynamic Contrast-Enhanced Magnetic Resonance Imaging Pharmacokinetic Parameters for Predicting Breast Cancers' Response to Neoadjuvant Chemotherapy. J Comput Assist Tomogr 2020;44:269-74. [PMID: 32195807 DOI: 10.1097/RCT.0000000000001001] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
7 Liang J, Cheng Q, Huang J, Ma M, Zhang D, Lei X, Xiao Z, Zhang D, Shi C, Luo L. Monitoring tumour microenvironment changes during anti-angiogenesis therapy using functional MRI. Angiogenesis 2019;22:457-70. [DOI: 10.1007/s10456-019-09670-4] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 5.3] [Reference Citation Analysis]
8 Giatromanolaki A, Kouroupi M, Kontomanolis EN, Koukourakis MI. Regulatory tumor-infiltrating lymphocytes prevail in endometrial tumors with low vascular survival ability. Immunobiology 2021;226:152078. [PMID: 33725493 DOI: 10.1016/j.imbio.2021.152078] [Reference Citation Analysis]
9 Zhao Z, Shuang T, Gao Y, Lu F, Zhang J, He W, Qu L, Chen B, Hao Q. Targeted delivery of exosomal miR-484 reprograms tumor vasculature for chemotherapy sensitization. Cancer Letters 2022. [DOI: 10.1016/j.canlet.2022.01.011] [Reference Citation Analysis]
10 Erin N, Grahovac J, Brozovic A, Efferth T. Tumor microenvironment and epithelial mesenchymal transition as targets to overcome tumor multidrug resistance. Drug Resist Updat 2020;53:100715. [PMID: 32679188 DOI: 10.1016/j.drup.2020.100715] [Cited by in Crossref: 33] [Cited by in F6Publishing: 37] [Article Influence: 16.5] [Reference Citation Analysis]
11 Abou Khouzam R, Brodaczewska K, Filipiak A, Zeinelabdin NA, Buart S, Szczylik C, Kieda C, Chouaib S. Tumor Hypoxia Regulates Immune Escape/Invasion: Influence on Angiogenesis and Potential Impact of Hypoxic Biomarkers on Cancer Therapies. Front Immunol 2020;11:613114. [PMID: 33552076 DOI: 10.3389/fimmu.2020.613114] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
12 Wagner KD, El Maï M, Ladomery M, Belali T, Leccia N, Michiels JF, Wagner N. Altered VEGF Splicing Isoform Balance in Tumor Endothelium Involves Activation of Splicing Factors Srpk1 and Srsf1 by the Wilms' Tumor Suppressor Wt1. Cells 2019;8:E41. [PMID: 30641926 DOI: 10.3390/cells8010041] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 6.0] [Reference Citation Analysis]
13 Fan Q, Tao Z, Yang H, Shi Q, Wang H, Jia D, Wan L, Zhang J, Cheng J, Lu X. Modulation of pericytes by a fusion protein comprising of a PDGFRβ-antagonistic affibody and TNFα induces tumor vessel normalization and improves chemotherapy. J Control Release 2019;302:63-78. [PMID: 30930215 DOI: 10.1016/j.jconrel.2019.03.018] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
14 Hauge A, Gaustad JV, Huang R, Simonsen TG, Wegner CS, Andersen LMK, Rofstad EK. DCE-MRI and Quantitative Histology Reveal Enhanced Vessel Maturation but Impaired Perfusion and Increased Hypoxia in Bevacizumab-Treated Cervical Carcinoma. Int J Radiat Oncol Biol Phys 2019;104:666-76. [PMID: 30858145 DOI: 10.1016/j.ijrobp.2019.03.002] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
15 Pan MR, Hou MF, Ou-Yang F, Wu CC, Chang SJ, Hung WC, Yip HK, Luo CW. FAK is Required for Tumor Metastasis-Related Fluid Microenvironment in Triple-Negative Breast Cancer. J Clin Med 2019;8:E38. [PMID: 30609732 DOI: 10.3390/jcm8010038] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 3.7] [Reference Citation Analysis]
16 Jarosz-Biej M, Smolarczyk R, Cichoń T, Kułach N. Tumor Microenvironment as A "Game Changer" in Cancer Radiotherapy. Int J Mol Sci 2019;20:E3212. [PMID: 31261963 DOI: 10.3390/ijms20133212] [Cited by in Crossref: 68] [Cited by in F6Publishing: 66] [Article Influence: 22.7] [Reference Citation Analysis]
17 Orecchia P, Balza E, Pietra G, Conte R, Bizzarri N, Ferrero S, Mingari MC, Carnemolla B. L19-IL2 Immunocytokine in Combination with the Anti-Syndecan-1 46F2SIP Antibody Format: A New Targeted Treatment Approach in an Ovarian Carcinoma Model. Cancers (Basel) 2019;11:E1232. [PMID: 31443604 DOI: 10.3390/cancers11091232] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
18 Aguilar-Cazares D, Chavez-Dominguez R, Carlos-Reyes A, Lopez-Camarillo C, Hernadez de la Cruz ON, Lopez-Gonzalez JS. Contribution of Angiogenesis to Inflammation and Cancer. Front Oncol 2019;9:1399. [PMID: 31921656 DOI: 10.3389/fonc.2019.01399] [Cited by in Crossref: 62] [Cited by in F6Publishing: 54] [Article Influence: 20.7] [Reference Citation Analysis]
19 Kanthou C, Tozer G. Targeting the vasculature of tumours: combining VEGF pathway inhibitors with radiotherapy. Br J Radiol 2019;92:20180405. [PMID: 30160184 DOI: 10.1259/bjr.20180405] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
20 Li Y, Liu Y, Du B, Cheng G. Reshaping Tumor Blood Vessels to Enhance Drug Penetration with a Multistrategy Synergistic Nanosystem. Mol Pharmaceutics 2020;17:3151-64. [DOI: 10.1021/acs.molpharmaceut.0c00077] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
21 Yang T, Xiao H, Liu X, Wang Z, Zhang Q, Wei N, Guo X. Vascular Normalization: A New Window Opened for Cancer Therapies. Front Oncol 2021;11:719836. [PMID: 34476218 DOI: 10.3389/fonc.2021.719836] [Reference Citation Analysis]
22 Liu J, Chen J, Liu H, Zhang K, Zeng Q, Yang S, Jiang Z, Zhang X, Chen T, Li D, Shan H. Bi/Se-Based Nanotherapeutics Sensitize CT Image-Guided Stereotactic Body Radiotherapy through Reprogramming the Microenvironment of Hepatocellular Carcinoma. ACS Appl Mater Interfaces 2021;13:42473-85. [PMID: 34474563 DOI: 10.1021/acsami.1c11763] [Reference Citation Analysis]
23 Malapelle U, Rossi A. Emerging angiogenesis inhibitors for non-small cell lung cancer. Expert Opinion on Emerging Drugs 2019;24:71-81. [DOI: 10.1080/14728214.2019.1619696] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]